Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1984)
  2. Solid Tumor Oncology Division (1616)
  3. GSK Faculty (762)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (413)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2092)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (89)
  5. Editorial (80)
  6. Guidelines (36)
  7. Correspondence (24)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1984)
  2. Solid Tumor Oncology Division (1616)
  3. GSK Faculty (762)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (80)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1668)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (209)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4627)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of commercially approved BCMAtargeting CAR-T therapy in triple-class refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Sean, M. D.; Parastoo, D.; Heather, J. L.; Oscar, B. L.; Michael, S.; Gunjan, L. S.; David, J. C.; Hani, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC
    Meeting Abstract

    Hayashi, H.; Yu, H. A.; Baik, C.; Kim, D. W.; Johnson, M. L.; Nishio, M.; Yang, J. C. H.; Su, W. C.; Gold, K. A.; Koczywas, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04
    Meeting Abstract

    Tsurutani, J.; Modi, S.; Sohn, J. H.; Tokunaga, E.; Niikura, N.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Wang, X.; Li, W.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer
    Meeting Abstract

    Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Stadler, Z.; Yaeger, R.; Smith, J. J.; Saltz, L.; Widmar, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis
    Meeting Abstract

    El Chaer, F.; Yuda, J.; Mccloskey, J.; Rein, L.; Brown, R.; Green, S.; Pu, J.; Shirane, S.; Shimoda, K.; Ichii, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
    Meeting Abstract

    Chi, K. N. N.; Castro, E.; Attard, G.; Smith, M. R.; Sandhu, S. K.; Efstathiou, E.; Roubaud, G.; Small, E. J. J.; Gomes, A. J. P. D. S; Rathkopf, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
    Meeting Abstract

    Jones, R. L.; Sanfilippo, R.; Schuetze, S. M.; Sebio, A.; Alvarez, R. M.; Bui, N.; Wagner, A. J.; Chawla, S. P.; Chen, T. W. W.; Pink, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaïve, RET-mutant medullary thyroid cancer
    Meeting Abstract

    Hadoux, J.; Elisei, R.; Brose, M. S.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Oh, D. Y.; Omori, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save